Baxalta/Shire, a global leader in biologic medical therapies, is building a state-of-the-art manufacturing facility in Stanton Springs to support growth of its plasma-based treatments used for immune disorders, trauma and other critical conditions.

Baxalta/Shire expects its capital investments at Stanton Springs to exceed $1 billion, resulting in more than 1,500 new full-time positions in Georgia and another 500+ across multiple U.S. locations.

In 2015, construction began on operations supporting plasma fractionation, purification, fill-finish and a testing lab. Commercial production is scheduled to begin in 2018, with the new plasma fractionation facility adding up to three million liters of new capacity annually when fully operational. The facility will have the flexibility and necessary infrastructure to expand further to support additional global market needs.

For more information about Shire visit www.shire.com